tenofovir
tenofovir: 7 clinical trials tracked.
tenofovir evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
What is verified about tenofovir, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (7)
Comparative Study on Antiviral Efficacy and Safety of Ainuovirine/Lamivudine/Tenofovir Versus Efavirenz/Lamivudine/Tenofovir Regimen in HIV Patients With Active Tuberculosis Infection: A Two-stage Prospective Multicenter Clinical Study
Primary endpoint: Viral suppression rates of two antiretroviral therapy(ART) regimens at week 48
Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome
Primary endpoint: Change in interferon activation as measured by interferon response genes
A Sequential Phase 1a/1b Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ARC-521 in Normal Adult Volunteers and Patients With Chronic Hepatitis B
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs): Healthy Volunteers
A Multicenter, Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis B Virus (HBV) Infection
Primary endpoint: Percentage of Initial Responders to ARC-520 Therapy Achieving a 1-log Reduction in HBsAg at Week 36 Compared to Baseline
A Multicenter, Randomized, Double-blind, Placebo-controlled Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection
Primary endpoint: Change From Baseline in Quantitative Hepatitis B Surface Antigen (Log qHBsAg) at Day 113
A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Negative, Chronic Hepatitis B Virus (HBV) Infection
Primary endpoint: Change From Baseline in Quantitative Hepatitis B Surface Antigen (Log qHBsAg) at Day 113
A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection
Primary endpoint: Change From Baseline in Quantitative Hepatitis B Surface Antigen (Log qHBsAg) at Day 85